Overview


The global topical atopic dermatitis treatment market is segmented into Drug Class, Distribution Channels, and Regions. The global market is projected account for USD 3,291.7 Mn in 2024 and to grow at a CAGR of 8.5% through 2032.

The global market is estimated to grow 1.63x between 2024 and 2032 creating an absolute $ opportunity of more than USD 2.5 Mn Based on drug class, the market is segmented into brain topical JAK inhibitor, topical calcineurin inhibitors, topical PDE4 inhibitors, topical corticosteroids, and other therapies/drug class. Among drug class, topical JAK inhibitor accounts for nearly 31.6% of the share in 2023 in the market with CAGR of 9.8% during the forecast period till 2032.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Topical Atopic Dermatitis Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Topical Atopic Dermatitis Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc
  • Novartis AG
  • Bayer AG
  • Japan Tobacco Inc.
  • Viatris
  • Teva Pharmaceuticals
  • Astellas Pharma Inc.
  • Incyte
  • Oneness Biotech Co, Ltd.
  • DS Biopharma
  • Arcutis Biotherapeutics
  • Dermvant Science, Inc
  • AbbVie
  • Sanofi S.A.
  • Eli Lilly and Company
  • Galderma S.A.
  • Vanda Pharmaceutical Inc
  • Cara Therapeutics
  • Oneness Biotech Co, Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Topical JAK Inhibitor
  • Topical Calcineurin Inhibitors
  • Topical PDE4 Inhibitors
  • Topical Corticosteroids
  • Other Therapies/Drug Class

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Topical Atopic Dermatitis Treatment Market By Drug Class, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Topical Atopic Dermatitis Treatment Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Topical Atopic Dermatitis Treatment Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Topical Atopic Dermatitis Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Topical Atopic Dermatitis Treatment Market, By Drug Class Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Topical JAK Inhibitor
      2. Topical Calcineurin Inhibitors
      3. Topical PDE4 Inhibitors
      4. Topical Corticosteroids
      5. Other Therapies/Drug Class
  • 8.  Topical Atopic Dermatitis Treatment Market, By Distribution Channels Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
  • 9.  North America Topical Atopic Dermatitis Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.  Latin America Topical Atopic Dermatitis Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.  Europe Topical Atopic Dermatitis Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.  Asia Pacific Topical Atopic Dermatitis Treatment Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 13.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
    •    1. Pfizer Inc
        1.1. Company Overview
        1.2. Drug Type Portfolio
        1.3. SWOT Analysis
        1.4. Financial Overview
        1.5. Strategic Overview
         2. Novartis AG
        2.1. Company Overview
        2.2. Drug Type Portfolio
        2.3. SWOT Analysis
        2.4. Financial Overview
        2.5. Strategic Overview
         3. Bayer AG
        3.1. Company Overview
        3.2. Drug Type Portfolio
        3.3. SWOT Analysis
        3.4. Financial Overview
        3.5. Strategic Overview
         4. Japan Tobacco Inc.
        4.1. Company Overview
        4.2. Drug Type Portfolio
        4.3. SWOT Analysis
        4.4. Financial Overview
        4.5. Strategic Overview
         5. Viatris
        5.1. Company Overview
        5.2. Drug Type Portfolio
        5.3. SWOT Analysis
        5.4. Financial Overview
        5.5. Strategic Overview
         6. Teva Pharmaceuticals
        6.1. Company Overview
        6.2. Drug Type Portfolio
        6.3. SWOT Analysis
        6.4. Financial Overview
        6.5. Strategic Overview
         7. Astellas Pharma Inc.
        7.1. Company Overview
        7.2. Drug Type Portfolio
        7.3. SWOT Analysis
        7.4. Financial Overview
        7.5. Strategic Overview
         8. Incyte
        8.1. Company Overview
        8.2. Drug Type Portfolio
        8.3. SWOT Analysis
        8.4. Financial Overview
        8.5. Strategic Overview
         9. Oneness Biotech Co, Ltd.
        9.1. Company Overview
        9.2. Drug Type Portfolio
        9.3. SWOT Analysis
        9.4. Financial Overview
        9.5. Strategic Overview
        10. DS Biopharma
        10.1. Company Overview
        10.2. Drug Type Portfolio
        10.3. SWOT Analysis
        10.4. Financial Overview
        10.5. Strategic Overview
        11. Arcutis Biotherapeutics
        11.1. Company Overview
        11.2. Drug Type Portfolio
        11.3. SWOT Analysis
        11.4. Financial Overview
        11.5. Strategic Overview
        12. Dermvant Science, Inc
        12.1. Company Overview
        12.2. Drug Type Portfolio
        12.3. SWOT Analysis
        12.4. Financial Overview
        12.5. Strategic Overview
        13. AbbVie
        13.1. Company Overview
        13.2. Drug Type Portfolio
        13.3. SWOT Analysis
        13.4. Financial Overview
        13.5. Strategic Overview
        14. Sanofi S.A.
        14.1. Company Overview
        14.2. Drug Type Portfolio
        14.3. SWOT Analysis
        14.4. Financial Overview
        14.5. Strategic Overview
        15. Eli Lilly and Company
        15.1. Company Overview
        15.2. Drug Type Portfolio
        15.3. SWOT Analysis
        15.4. Financial Overview
        15.5. Strategic Overview
        16. Galderma S.A.
        16.1. Company Overview
        16.2. Drug Type Portfolio
        16.3. SWOT Analysis
        16.4. Financial Overview
        16.5. Strategic Overview
        17. Vanda Pharmaceutical Inc
        17.1. Company Overview
        17.2. Drug Type Portfolio
        17.3. SWOT Analysis
        17.4. Financial Overview
        17.5. Strategic Overview
        18. Cara Therapeutics
        18.1. Company Overview
        18.2. Drug Type Portfolio
        18.3. SWOT Analysis
        18.4. Financial Overview
        18.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •      

Partner

Our Clients